2.63 EUR
2.54 B EUR
13.08 B EUR
970.30 M
About CSL Limited
Sector
Industry
CEO
Paul McKenzie
Website
Headquarters
Melbourne
Founded
1961
ISIN
US12637N2045
FIGI
BBG0074TGMC7
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.
CSLF5781464
CSL Finance Plc 5.417% 03-APR-2054Yield to maturity
5.97%
Maturity date
Apr 3, 2054
CSLF5401478
CSL Finance Plc 4.75% 27-APR-2052Yield to maturity
5.70%
Maturity date
Apr 27, 2052
CSLF5401480
CSL Finance Plc 4.95% 27-APR-2062Yield to maturity
5.35%
Maturity date
Apr 27, 2062
CSLF5401476
CSL Finance Plc 4.625% 27-APR-2042Yield to maturity
5.20%
Maturity date
Apr 27, 2042
CSLF5401474
CSL Finance Plc 4.25% 27-APR-2032Yield to maturity
4.60%
Maturity date
Apr 27, 2032
CSLF5781462
CSL Finance Plc 5.106% 03-APR-2034Yield to maturity
4.53%
Maturity date
Apr 3, 2034
CSLF5401472
CSL Finance Plc 4.05% 27-APR-2029Yield to maturity
4.23%
Maturity date
Apr 27, 2029
CSLF5401470
CSL Finance Plc 3.85% 27-APR-2027Yield to maturity
4.11%
Maturity date
Apr 27, 2027
See all CSJA bonds